Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial
详细信息 查看全文
- 作者：Andrew J. Armstrong ; Michael S. Humeniuk ; Patrick Healy ; Russell Szmulewitz ; Carolyn Winters ; Julie Kephart ; Michael R. Harrison ; Elia Martinez ; Kelly Mundy ; Susan Halabi and Daniel George
- 刊名：The Prostate
- 出版年：2017
- 出版时间：March 1, 2017
- 年：2017
- 卷：77
- 期：4
- 页码：385-395
- 全文大小：519K
- ISSN：1097-0045
文摘
Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single agent activity and in combination with taxanes. We sought to identify the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of tasquinimod in combination with cabazitaxel and prednisone in men with chemorefractory mCRPC.